NCT07299071 Efficacy of CAD in Screening Colonoscopy to Reduce the Risk of Advanced Adenoma at 3 Years.
| NCT ID | NCT07299071 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Bordeaux |
| Condition | Colonoscopy |
| Study Type | INTERVENTIONAL |
| Enrollment | 592 participants |
| Start Date | 2026-03-13 |
| Primary Completion | 2031-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 592 participants in total. It began in 2026-03-13 with a primary completion date of 2031-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The occurrence of interval cancers after colonoscopy raises the possibility of missed lesions. High- performance computer aided diagnosis (CAD) systems have been specially designed for the detection of colorectal lesions (CAD for detection is named CADe). The use of CADe improves adenoma detection in screening colonoscopy. The potential of CADe system in reducing the rate of progression to advanced polyps or interval cancer between two colonoscopies remains still uncertain.
Eligibility Criteria
Inclusion Criteria: * Patients over 18 years of age with indication for colonoscopy as part of a screening program, after a positive immunological (FIT) test, and/or for personal or family history of colorectal cancer and/or personal history of colonic adenomas, * Written informed consent signed * Patients covered by a health-care insurance. Exclusion Criteria: * Failed complete colonoscopy, defined by the absence of cecal intubation and/or the absence of terminal ileum cauterization * Inadequate bowel preparation (Boston bowel preparation score \< 6, and/or least at one part of colon with score ≤ 1) * An infiltrative tumor was diagnosed during colonoscope insertion time, not accessible to endoscopic resection and likely to require surgical management (a procedure where part of the colon may need to be removed). * Patient under guardianship or protection * Pregnant women * Not fluent in French or illiterate * Personal history of inflammatory bowel disease * Personal history of genetic predisposition of CRC * Personal history of colonic surgery
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07299071 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Colonoscopy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07299071 currently recruiting?
Yes, NCT07299071 is actively recruiting participants. Contact the research team at arthur.berger@chu-bordeaux.fr for enrollment information.
Where is the NCT07299071 trial being conducted?
This trial is being conducted at Bayonne, France, Brest, France, Charenton-le-Pont, France, Limoges, France and 9 additional locations.
Who is sponsoring the NCT07299071 clinical trial?
NCT07299071 is sponsored by University Hospital, Bordeaux. The trial plans to enroll 592 participants.